首页> 美国卫生研究院文献>Contrast Media Molecular Imaging >Physiologically Based Pharmacokinetic Modelling with Dynamic PET Data to Study the In Vivo Effects of Transporter Inhibition on Hepatobiliary Clearance in Mice
【2h】

Physiologically Based Pharmacokinetic Modelling with Dynamic PET Data to Study the In Vivo Effects of Transporter Inhibition on Hepatobiliary Clearance in Mice

机译:基于生理学的药代动力学模型与动态PET数据研究转运蛋白抑制剂对小鼠肝胆清除率的体内作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Physiologically based pharmacokinetic modelling (PBPK) is a powerful tool to predict in vivo pharmacokinetics based on physiological parameters and data from in vivo studies and in vitro assays. In vivo PBPK modelling in laboratory animals by noninvasive imaging could help to improve the in vivo-in vivo translation towards human pharmacokinetics modelling. We evaluated the feasibility of PBPK modelling with PET data from mice. We used data from two of our PET tracers under development, [11C]AM7 and [11C]MT107. PET images suggested hepatobiliary excretion which was reduced after cyclosporine administration. We fitted the time-activity curves of blood, liver, gallbladder/intestine, kidney, and peripheral tissue to a compartment model and compared the resulting pharmacokinetic parameters under control conditions ([11C]AM7 n = 2; [11C]MT107, n = 4) and after administration of cyclosporine ([11C]MT107, n = 4). The modelling revealed a significant reduction in [11C]MT107 hepatobiliary clearance from 35.2 ± 10.9 to 17.1 ± 5.6 μl/min after cyclosporine administration. The excretion profile of [11C]MT107 was shifted from predominantly hepatobiliary (CLH/CLR = 3.8 ± 3.0) to equal hepatobiliary and renal clearance (CLH/CLR = 0.9 ± 0.2). Our results show the potential of PBPK modelling for characterizing the in vivo effects of transporter inhibition on whole-body and organ-specific pharmacokinetics.
机译:基于生理学的药代动力学建模(PBPK)是基于生理参数和来自体内研究和体外测定的数据预测体内药代动力学的强大工具。通过无创成像在实验动物中进行体内PBPK建模可以帮助改善体内对人药代动力学建模的体内翻译。我们用小鼠的PET数据评估了PBPK建模的可行性。我们使用了两个正在开发的PET示踪剂的数据,即[ 11 C] AM7和[ 11 C] MT107。 PET图像提示肝胆汁排泄在环孢霉素给药后减少。我们将血液,肝脏,胆囊/肠,肾脏和周围组织的时间-活动曲线拟合到一个区室模型,并比较了在对照条件下的所得药代动力学参数([ 11 C] AM7 n = 2 ; [ 11 C] MT107,n = 4)和环孢菌素给药后[[ 11 C] MT107,n = 4)。该模型显示,环孢菌素给药后[ 11 C] MT107肝胆清除率从35.2±10.9显着降低至17.1±5.6μl/ min。 [ 11 C] MT107的排泄曲线从主要的肝胆(CLH / CLR = 3.8±3.0)变为相等的肝胆和肾脏清除率(CLH / CLR = 0.9±0.2)。我们的结果表明,PBPK模型可用于表征转运蛋白抑制作用在体内对全身和器官特异性药代动力学的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号